Patent application number | Description | Published |
20080287578 | Coupling Agents Between Filler and Elastomer - The invention describes a composition comprising a) a naturally occurring or synthetic elastomer susceptible to oxidative, thermal, dynamic, light-induced and/or ozone-induced degradation, b) a white reinforcing filler, and c) as coupling agent, at least one compound of the formula (I) wherein the general symbols are as defined in claim | 11-20-2008 |
20090144915 | Graftable hindered amine light stabilizers - The invention describes novel compound of the formula I, | 06-11-2009 |
20090306256 | Styrene butadiene styrene block copolymer based adhesive compositions with improved photo-oxidation resistance - The instant invention relates to styrene butadiene styrene based pressure sensitive adhesive compositions with improved photo-oxidation resistance containing N-methyl substituted sterically hindered amines as stabilizers. Further aspects of the invention are a process for the stabilization of butadiene based pressure sensitive adhesive compositions and the use of N-methyl substituted sterically hindered amines as stabilizers for styrene butadiene styrene based pressure sensitive adhesives. | 12-10-2009 |
20100130660 | PROCESSING STABILIZERS FOR RUBBER COMPOUNDING - The invention describes an improved method for the preparation of rubber compounds which comprises compounding the rubber and the components at 125-200° C. in the presence of an amount of 0.1-2% based on the weight of the rubber of a processing stabilizer of the formula (I) wherein R | 05-27-2010 |
20100317778 | Filled Rubber Compounds with Improved Processability - The invention describes a process for the manufacture of a filled rubber compound with improved processability which comprises mixing in one-step a) a rubber, b) a white reinforcing filler, and c) a coupling agent of the Formula (I), wherein the general symbols are as defined in claim | 12-16-2010 |
Patent application number | Description | Published |
20090117120 | Transgenic animal model for alzheimer's disease - Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods. | 05-07-2009 |
20100048687 | USE OF PHOSPHATASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described. | 02-25-2010 |
20100202968 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 08-12-2010 |
20110086908 | USE OF PHOSPHATASE INHIBITORS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES - Provided are novel a target and drugs in the treatment of neurological disorders related to amyloid beta pathology/amyloidosis. More specifically, the use of phosphatase inhibitors for the treatment of brain impairments mediated by Aβ-oligomers is described. | 04-14-2011 |
20130266514 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 10-10-2013 |
20130266585 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 10-10-2013 |
20130266586 | Method of Providing Disease-Specific Binding Molecules and Targets - Provided are novel specific binding molecules, particularly human antibodies as well as fragments, derivatives and variants thereof that recognize neoepitopes of disease-associated proteins which derive from native endogenous proteins but are prevalent in the body of a patient in a variant form and/or out of their normal physiological context. In addition, pharmaceutical compositions comprising such binding molecules, antibodies and mimics thereof and methods of screening for novel binding molecules, which may or may not be antibodies as well as targets in the treatment of neurological disorders such as Alzheimer's disease are described. | 10-10-2013 |